The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.

MLA

Choi, Joon Ho, et al. “The Role of 18F-FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma after Radioimmunotherapy Using 131I-Rituximab as Consolidation Therapy.” PloS One, vol. 17, no. 9, Sept. 2022, p. e0273839. EBSCOhost, https://doi.org/10.1371/journal.pone.0273839.

APA

Choi, J. H., Lim, I., Byun, B. H., Kim, B. I., Choi, C. W., Kang, H. J., Shin, D.-Y., & Lim, S. M. (2022). The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. PloS One, 17(9), e0273839. https://doi.org/10.1371/journal.pone.0273839

Chicago

Choi, Joon Ho, Ilhan Lim, Byung Hyun Byun, Byung Il Kim, Chang Woon Choi, Hye Jin Kang, Dong-Yeop Shin, and Sang Moo Lim. 2022. “The Role of 18F-FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma after Radioimmunotherapy Using 131I-Rituximab as Consolidation Therapy.” PloS One 17 (9): e0273839. doi:10.1371/journal.pone.0273839.